已核实 DOI PubMed 相关产品: 4

Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro

Journal 2020 · IF 4.101 · 发表于 2020 年 6 月 21 日
作者: Zhanding Cui,Dengliang Li,Yinli Xie,Kai Wang,Ying Zhang,Guohua Li,Qian Zhang,Xiaoxueying Chen,Yue Teng,Shihui Zhao,Jiang Shao,Fan Xingmeng,Yanli Zhao,Dongju Du,Yanbing Guo,Hailong Huang,Hao Dong,Guixue Hu,Shuang Zhang,Yongkun Zhao
阅读全文 在 PubMed 查看

摘要

Feline calicivirus (FCV) is a highly contagious pathogen that causes acute upper respiratory infections and oral disease in cats, thus seriously endangering feline health. Recently, there have been outbreaks of particularly virulent variant strains of FCV, which can cause both acute symptoms and fatal systemic disease. The discovery of effective antiviral agents to treat FCV infection is, therefore, gradually assuming increased importance. In this study, we showed that both nitazoxanide and mizoribine had antiviral activity in F81 cells infected with different strains of FCV and also demonstrated a synergistic effect between the two drugs. Experiments in cats challenged with FCV showed that nitazoxanide significantly reduced the clinical symptoms of FCV infection, reduced viral load in the trachea and lungs, and reduced viral shedding. Our results showed that nitazoxanide and mizoribine could potentially be used as therapeutic agents to treat FCV infection.

本研究中使用的阿拉丁产品

4 款产品在本文中被引用